Emgality reduced the impact on daily activities and severity of migraine1

Emgality significantly reduced the impact of migraine on daily activities over Months 4 to 6 (p<0.001), as assessed by a validated functional impact tool.1,7,8

The impact of migraine on daily activities was assessed using the Role Function-Restrictive domain of the MSQ v2.1. MSQ v2.1 is a self-administered tool developed to assess the impact of migraine on patients’ health-related quality of life.1,7,8

  • Areas measured included relationships with family and friends, leisure time, productivity, concentration, energy, and tiredness8
  • Scores are scaled from 0 to 100, with higher scores indicating less impact of migraine on daily activities1
Emgality mean improvement
  • In EVOLVE-1, Emgality demonstrated a mean improvement of 32.4 points from baseline (N=189) vs 24.7 points with placebo (N=377) over Months 4 to 6 (baseline: 51.5 points vs 52.9 points) (p<0.001)1
Emgality improvement over placebo
  • In EVOLVE-2, Emgality demonstrated a mean improvement of 28.5 points from baseline (N=213) vs 19.7 points with placebo (N=396) over Months 4 to 6 (baseline: 51.7 points vs 51.4 points) (p<0.001)1

Emgality significantly improved patients’ impression of the severity of their disease vs placebo, on average over Months 4 to 6 (p=0.002)6

  • EVOLVE-1: Mean change from baseline in PGI-S score was -1.59 for Emgality vs -1.27 for placeboa
  • EVOLVE-2: Mean change from baseline in PGI-S score was -1.22 for Emgality vs -0.94 for placeboa

aEVOLVE-1: Emgality 120 mg (N=189), placebo (N=377); EVOLVE-2: Emgality 120 mg (N=213), placebo (N=396).

SELECT IMPORTANT SAFETY INFORMATION
ADVERSE REACTIONS

The most common adverse reactions (incidence ≥2% and at least 2% greater than placebo) in Emgality clinical studies were injection site reactions.

Indications and Important Safety Information
Indications

Emgality is a calcitonin gene-related peptide (CGRP) antagonist indicated for the preventive treatment of migraine in adults.

Important Safety Information

CONTRAINDICATIONS
Emgality is contraindicated in patients with serious hypersensitivity to galcanezumab-gnlm or to any of the excipients.


WARNINGS AND PRECAUTIONS
Hypersensitivity Reactions
Hypersensitivity reactions (e.g., rash, urticaria, and dyspnea) have been reported with Emgality in clinical studies. If a serious or severe hypersensitivity reaction occurs, discontinue administration of Emgality and initiate appropriate therapy. Hypersensitivity reactions can occur days after administration and may be prolonged.


ADVERSE REACTIONS
The most common adverse reactions (incidence ≥2% and at least 2% greater than placebo) in Emgality clinical studies were injection site reactions.


Emgality is available by prescription only.


Please see Full Prescribing Information, including Patient Information for Emgality. See Instructions for Use included with the pen and prefilled syringe.


GZ HCP ISI 27SEP2018